Legal Representation
Attorney
Jeremy Blackowicz
USPTO Deadlines
Next Deadline
2098 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20251104)
Due Date
November 04, 2031
Grace Period Ends
May 04, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 18, 2025 | RHRD | I | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | Loading... |
| Nov 4, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 4, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Sep 16, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 16, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 10, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 29, 2025 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 19, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 18, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 18, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 18, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 14, 2025 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 13, 2025 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jul 2, 2025 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jul 1, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 26, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 16, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Mar 16, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 13, 2025 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of autoimmune conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of blood conditions, diseases and disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the prevention and treatment of conditions, diseases, and disorders of the central and peripheral nervous system; pharmaceutical preparations for the prevention and treatment of dermatological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of endocrine conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of gastrointestinal conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of hepatic conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of immunological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of infectious diseases; pharmaceutical preparations for the prevention and treatment of inflammatory conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of metabolic conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of muscular conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of neurological conditions, diseases, and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the prevention and treatment of psychiatric conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of respiratory and pulmonary conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of renal conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of urological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of viral diseases.
Classification
International Classes
005